NASDAQ$FDMT
4D Molecular Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported full year 2023 financial results and provided operational highlights.
4D Molecular Therapeutics reported a transformative year in 2023, marked by significant progress in its product pipeline and platform across multiple therapeutic areas. The company highlighted positive interim data from the Phase 2 PRISM study of 4D-150 in wet AMD, advancements in clinical trials for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease, and strategic agreements with Astellas Pharma and Arbor Biotechnologies. 4DMT's cash position was strengthened by a completed public follow-on offering, extending its operational runway into the first half of 2027.
- Presented positive interim data from the Phase 2 PRISM study of 4D-150 in wet AMD, enabling Phase 3 pivotal development.
- Demonstrated positive interim clinical data for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease.
- Secured strategic agreements with Astellas Pharma in rare monogenic retinal diseases and Arbor Biotechnologies in CNS gene editing.
- Completed an upsized public follow-on offering, supplementing cash position and extending operational runway into the first half of 2027.
Headline financials
Revenue & EPS history
4DMT · Revenue · Quarterly
-$17K
Revenue by segment
4DMT · $20.2M total across 1 segment · Q3 2023
- Collaboration & license rev.$20.2M+3940.8%100.0%
Forward guidance
4DMT anticipates several milestones in the near future across its key programs.
Tailwinds
- Initial interim 24-week landmark analysis for Phase 2 PRISM Population Extension cohort of 4D-150 for Wet AMD expected in Q3 2024.
- Additional FDA and EMA regulatory interactions for 4D-150 planned in Q2 2024, with an update expected in Q3 2024.
- Phase 3 clinical trial initiation for 4D-150 for Wet AMD expected in Q1 2025.
- Initial interim 24-week landmark data for Phase 2 SPECTRA clinical trial Dose Confirmation cohort of 4D-150 for DME expected in H2 2024.
- FDA submission of preclinical NHP safety data for 4D-310 for Fabry Disease Cardiomyopathy in combination with rituximab/sirolimus immunosuppression regimen expected in Q2 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+20.0%
Q3 2022
Best reaction
-10.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.6% | -0.7% | -17.3% | |
| Q4 2025 | +7.3% | +7.2% | +22.5% | |
| Q3 2025 | +6.7% | +6.1% | +7.4% | |
| Q1 2025 | +9.9% | +4.7% | +27.0% | |
| Q4 2024 | -8.6% | -8.6% | -28.7% | |
| Q3 2024 | +1.9% | +5.7% | -17.4% | |
| Q2 2024 | +0.6% | +1.6% | +2.4% | |
| Q1 2024 | -2.4% | -2.2% | -13.7% | |
| Q4 2023 | +5.3% | -3.0% | +14.2% | |
| Q3 2023 | +1.8% | +2.2% | +37.7% | |
| Q2 2023 | -1.6% | -1.1% | -7.4% | |
| Q1 2023 | -2.5% | +2.8% | +26.8% | |
| Q4 2022 | -0.7% | -5.4% | -12.5% | |
| Q3 2022 | +20.0% | +66.3% | +188.5% | |
| Q2 2022 | -10.4% | -12.5% | -14.9% | |
| Q1 2022 | -3.1% | -12.9% | -31.5% | |
| Q4 2021 | +8.1% | +1.6% | -22.5% | |
| Q3 2021 | -0.7% | -3.8% | -12.1% | |
| Q2 2021 | -4.0% | +5.2% | +19.4% | |
| Q1 2021 | -3.9% | -3.4% | +2.6% | |
| Q2 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro